143 related articles for article (PubMed ID: 38711220)
1. Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases.
Sevilla A; Grichnik J
Exp Dermatol; 2024 May; 33(5):e15091. PubMed ID: 38711220
[TBL] [Abstract][Full Text] [Related]
2. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
3. Autocrine/Paracrine Loop Between SCF
Annese T; Tamma R; Bozza M; Zito A; Ribatti D
Front Immunol; 2022; 13():794974. PubMed ID: 35140718
[TBL] [Abstract][Full Text] [Related]
4. Expression of Stem Cell Factor in Feline Mast Cell Tumour.
Sakurai M; Iwasa R; Sakai Y; Chambers JK; Uchida K; Morimoto M
J Comp Pathol; 2018 Aug; 163():6-9. PubMed ID: 30213375
[TBL] [Abstract][Full Text] [Related]
5. Targeting c-kit in the therapy of mast cell disorders: current update.
El-Agamy DS
Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours.
Takahashi H; Saitoh K; Kishi H; Parsons PG
Virchows Arch; 1995; 427(3):283-8. PubMed ID: 7496598
[TBL] [Abstract][Full Text] [Related]
7. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
Cruse G; Metcalfe DD; Olivera A
Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
[TBL] [Abstract][Full Text] [Related]
8. A fully human anti-c-Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells.
Kim KH; Kim JO; Park SG
Mol Cell Biochem; 2023 Apr; 478(4):861-873. PubMed ID: 36107283
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.
Jensen BM; Akin C; Gilfillan AM
Br J Pharmacol; 2008 Aug; 154(8):1572-82. PubMed ID: 18500355
[TBL] [Abstract][Full Text] [Related]
10. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
11. Molecular defects in mastocytosis: KIT and beyond KIT.
Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
[TBL] [Abstract][Full Text] [Related]
12. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
13. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis.
Longley BJ; Morganroth GS; Tyrrell L; Ding TG; Anderson DM; Williams DE; Halaban R
N Engl J Med; 1993 May; 328(18):1302-7. PubMed ID: 7682288
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
Bibi S; Arock M
Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
[TBL] [Abstract][Full Text] [Related]
15. SCF/c-kit signaling is required in 12-O-tetradecanoylphorbol-13-acetate-induced migration and differentiation of hair follicle melanocytes for epidermal pigmentation.
Qiu W; Yang K; Lei M; Yan H; Tang H; Bai X; Yang G; Lian X; Wu J
Cell Tissue Res; 2015 May; 360(2):333-46. PubMed ID: 25727244
[TBL] [Abstract][Full Text] [Related]
16. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
17. Stem Cell Factor-Inducible MITF-M Expression in Therapeutics for Acquired Skin Hyperpigmentation.
Yun CY; Roh E; Kim SH; Han J; Lee J; Jung DE; Kim GH; Jung SH; Cho WJ; Han SB; Kim Y
Theranostics; 2020; 10(1):340-352. PubMed ID: 31903124
[No Abstract] [Full Text] [Related]
18. KIT as a master regulator of the mast cell lineage.
Tsai M; Valent P; Galli SJ
J Allergy Clin Immunol; 2022 Jun; 149(6):1845-1854. PubMed ID: 35469840
[TBL] [Abstract][Full Text] [Related]
19. RIN3 is a negative regulator of mast cell responses to SCF.
Janson C; Kasahara N; Prendergast GC; Colicelli J
PLoS One; 2012; 7(11):e49615. PubMed ID: 23185384
[TBL] [Abstract][Full Text] [Related]
20. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.
Galli SJ; Tsai M; Wershil BK
Am J Pathol; 1993 Apr; 142(4):965-74. PubMed ID: 7682764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
